In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SpineGuard: Taming Of The Screw

Executive Summary

Much of the innovation in spine over the past decade has aimed at replacing fusion, the standard of care. SpineGuard’s novel sensor technology is betting on fusion’s long-term prospects, helping patients and surgeons by making the procedure safer.

You may also be interested in...



SpineVision: Meeting the Competition Head On

Spine surgery has gone from the pariah of the orthopedic industry to that sector's fastest growing segment. Large companies have looked to capitalize on spine's rapid growth by acquiring their way into this space, a pattern of consolidation that has left the industry without a major pure play spinal company. SpineVision is looking to fill that void by developing a complete line of spinal products, starting with innovations on core technology, rather than relying on a typical start-up strategy of focusing on a particular device or clinical niche. The company's strategy will bring it immediately into competition with the market leaders' well-established product lines. But SpineVision is counting on experienced management and the current frustration among spine surgeons resulting from recent industry consolidation to attract physicians' attention.

Zydus Walks Away From US Dapagliflozin Appeal, ANDA Discontinued

In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.

Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO

After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV004068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel